carmustine has been researched along with Infections in 16 studies
Carmustine: A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index, 11th ed)
carmustine : A member of the class of N-nitrosoureas that is 1,3-bis(2-chloroethyl)urea in which one of the nitrogens is substituted by a nitroso group.
Infections: Invasion of the host organism by microorganisms or their toxins or by parasites that can cause pathological conditions or diseases.
| Excerpt | Relevance | Reference |
|---|---|---|
| "High-dose BEAM chemotherapy (BCNU, etoposide, Ara-C, and melphalan) followed by autologous hematopoietic stem cell transplantation is frequently used as consolidative therapy for patients with recurrent or refractory Hodgkin or non-Hodgkin lymphoma." | 3.83 | Outpatient administration of BEAM conditioning prior to autologous stem cell transplantation for lymphoma is safe, feasible, and cost-effective. ( Baran, A; Barr, PM; Becker, MW; Friedberg, JW; Liesveld, JL; Milner, LA; Phillips, GL; Reid, RM; Wedow, L, 2016) |
| "Severe infections were seen as often with VBMCP as with VBMCP + rIFN(alpha2) (13% vs." | 2.69 | The addition of interferon or high dose cyclophosphamide to standard chemotherapy in the treatment of patients with multiple myeloma: phase III Eastern Cooperative Oncology Group Clinical Trial EST 9486. ( Greipp, PR; Kay, NE; Keimowitz, RM; Kyle, RA; Lenhard, RE; Leong, T; Oken, MM; Van Ness, B, 1999) |
| "Sixty-five patients with hematological malignancies (25 multiple myeloma, 18 Hodgkin's disease, 22 non-Hodgkin's lymphomas) who received a carmustine-based regimen followed by autologous PBPC transplantation, were studied retrospectively to evaluate the incidence of post-transplant non-infective pulmonary complications (NIPCs), risk factors predictive of NIPCs, and response to steroids." | 2.69 | Pulmonary toxicity following carmustine-based preparative regimens and autologous peripheral blood progenitor cell transplantation in hematological malignancies. ( Alessandrino, EP; Bernasconi, C; Bernasconi, P; Caldera, D; Colombo, A; Klersy, C; Malcovati, L; Martinelli, G; Nascimbene, C; Varettoni, M; Vitulo, P; Volpini, E, 2000) |
| "We studied 19 breast cancer (BC) patients and 17 multiple myeloma (MM) patients entered in a high-dose chemotherapy (HDC) program of tandem autografting with CD34+ cell-selected PBPC." | 1.32 | Hemopoietic recovery and infectious complications in breast cancer and multiple myeloma after autologous CD34+ cell-selected peripheral blood progenitor cell transplantation. ( Amodeo, R; Anghel, G; De Rosa, L; Majolino, I; Pandolfi, A; Riccardi, M, 2004) |
| "The median time to disease progression and median survival were 1." | 1.31 | Four-cycle high-dose therapy with hematopoietic support for metastatic breast cancer: no improvement in outcomes compared with single-course high-dose therapy. ( Blume, KG; Chao, NJ; Feiner, RH; Hu, WW; Johnston, LJ; Long, GD; Negrin, RS; Shizuru, JA; Stockerl-Goldstein, K; Wong, RM, 2000) |
| "Despite the fact that follicular lymphomas are both chemo- and radiosensitive, the disease is generally non-curable." | 1.31 | Long-term follow-up of autologous stem-cell transplantation for follicular and transformed follicular lymphoma. ( Berglund, A; Carlson, K; Enblad, G; Glimelius, B; Hagberg, H, 2000) |
| " HDT appeared to be somewhat more toxic in the elderly patients: a higher peak CRP value (P = 0." | 1.31 | Feasibility and toxicity of high-dose chemotherapy supported by peripheral blood stem cell transplantation in elderly patients (>/=60 years) with non-Hodgkin's lymphoma: comparison with patients <60 years treated within the same protocol. ( Jantunen, E; Mahlamäki, E; Nousiainen, T, 2000) |
| " The results of this study demonstrate that the use of CD34(+) cells is safe and has no adverse effects either with respect to haematological, immune reconstitution or to infections after HDT." | 1.31 | High-dose therapy in patients with Hodgkin's disease: the use of selected CD34(+) cells is as safe as unmanipulated peripheral blood progenitor cells. ( Blystad, AK; Delabie, J; Holte, H; Kvalheim, G; Kvaløy, S; Smeland, E, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (18.75) | 18.7374 |
| 1990's | 1 (6.25) | 18.2507 |
| 2000's | 11 (68.75) | 29.6817 |
| 2010's | 1 (6.25) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Reid, RM | 1 |
| Baran, A | 1 |
| Friedberg, JW | 1 |
| Phillips, GL | 1 |
| Liesveld, JL | 1 |
| Becker, MW | 1 |
| Wedow, L | 1 |
| Barr, PM | 1 |
| Milner, LA | 1 |
| Rossi, HA | 1 |
| Becker, PS | 1 |
| Emmons, RV | 1 |
| Westervelt, P | 1 |
| Levy, W | 1 |
| Liu, Q | 1 |
| Clark, Y | 1 |
| Ballen, K | 1 |
| De Rosa, L | 1 |
| Anghel, G | 1 |
| Pandolfi, A | 1 |
| Riccardi, M | 1 |
| Amodeo, R | 1 |
| Majolino, I | 1 |
| Puig, N | 1 |
| de la Rubia, J | 1 |
| Remigia, MJ | 1 |
| Jarque, I | 1 |
| Martín, G | 1 |
| Cupelli, L | 1 |
| Sanz, GF | 1 |
| Lorenzo, I | 1 |
| Sanz, J | 1 |
| Martínez, JA | 1 |
| Jiménez, C | 1 |
| Sanz, MA | 1 |
| Liter, ME | 1 |
| Oken, MM | 1 |
| Leong, T | 1 |
| Lenhard, RE | 1 |
| Greipp, PR | 1 |
| Kay, NE | 1 |
| Van Ness, B | 1 |
| Keimowitz, RM | 1 |
| Kyle, RA | 1 |
| Alessandrino, EP | 1 |
| Bernasconi, P | 1 |
| Colombo, A | 1 |
| Caldera, D | 1 |
| Martinelli, G | 1 |
| Vitulo, P | 1 |
| Malcovati, L | 1 |
| Nascimbene, C | 1 |
| Varettoni, M | 1 |
| Volpini, E | 1 |
| Klersy, C | 1 |
| Bernasconi, C | 1 |
| Hu, WW | 1 |
| Negrin, RS | 1 |
| Stockerl-Goldstein, K | 1 |
| Johnston, LJ | 1 |
| Shizuru, JA | 1 |
| Wong, RM | 1 |
| Chao, NJ | 1 |
| Long, GD | 1 |
| Feiner, RH | 1 |
| Blume, KG | 1 |
| Kozák, T | 1 |
| Havrdová, E | 1 |
| Pit'ha, J | 1 |
| Gregora, E | 1 |
| Pytlík, R | 1 |
| Maaloufová, J | 1 |
| Marecková, H | 1 |
| Kobylka, P | 1 |
| Vodvárková, S | 1 |
| Berglund, A | 1 |
| Enblad, G | 1 |
| Carlson, K | 1 |
| Glimelius, B | 1 |
| Hagberg, H | 1 |
| Steingrimsdottir, H | 1 |
| Gruber, A | 1 |
| Björkholm, M | 1 |
| Svensson, A | 1 |
| Hansson, M | 1 |
| Jantunen, E | 1 |
| Mahlamäki, E | 1 |
| Nousiainen, T | 1 |
| Chandrasekar, PH | 1 |
| Abraham, OC | 1 |
| Klein, J | 1 |
| Alangaden, G | 1 |
| Chalasani, G | 1 |
| Cassells, L | 1 |
| Dansey, R | 1 |
| Abella, S | 1 |
| Karanes, C | 1 |
| Peters, W | 1 |
| Baynes, R | 1 |
| Blystad, AK | 1 |
| Holte, H | 1 |
| Kvaløy, S | 1 |
| Smeland, E | 1 |
| Delabie, J | 1 |
| Kvalheim, G | 1 |
| Hartmann, O | 1 |
| Benhamou, E | 1 |
| Beaujean, F | 1 |
| Kalifa, C | 1 |
| Lejars, O | 1 |
| Patte, C | 1 |
| Behard, C | 1 |
| Flamant, F | 1 |
| Thyss, A | 1 |
| Deville, A | 1 |
| Haghbin, M | 1 |
| Tan, CC | 1 |
| Clarkson, BD | 1 |
| Miké, V | 1 |
| Burchenal, JH | 1 |
| Murphy, ML | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized Phase II Trial Comparing BeEAM With BEAM as Conditioning Regimen for Autologous Stem Cell Transplantation (ASCT) in Lymphoma Patients (BEB-trial)[NCT02278796] | Phase 2 | 108 participants (Actual) | Interventional | 2015-04-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
5 trials available for carmustine and Infections
| Article | Year |
|---|---|
High-dose cyclophosphamide, BCNU, and VP-16 (CBV) conditioning before allogeneic stem cell transplantation for patients with non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Blood Plate | 2003 |
Morbidity and transplant-related mortality of CBV and BEAM preparative regimens for patients with lymphoid malignancies undergoing autologous stem-cell transplantation.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamid | 2006 |
The addition of interferon or high dose cyclophosphamide to standard chemotherapy in the treatment of patients with multiple myeloma: phase III Eastern Cooperative Oncology Group Clinical Trial EST 9486.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cardiovascular Disea | 1999 |
Pulmonary toxicity following carmustine-based preparative regimens and autologous peripheral blood progenitor cell transplantation in hematological malignancies.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Child; Child, Prescho | 2000 |
High-dose immunosuppressive therapy with PBPC support in the treatment of poor risk multiple sclerosis.
Topics: Adolescent; Adult; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Carmustine; CD4-CD8 | 2000 |
11 other studies available for carmustine and Infections
| Article | Year |
|---|---|
Outpatient administration of BEAM conditioning prior to autologous stem cell transplantation for lymphoma is safe, feasible, and cost-effective.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modali | 2016 |
Hemopoietic recovery and infectious complications in breast cancer and multiple myeloma after autologous CD34+ cell-selected peripheral blood progenitor cell transplantation.
Topics: Adult; Aged; Antibiotic Prophylaxis; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasm | 2004 |
Management of drug toxicities and infections.
Topics: Antineoplastic Agents; Carmustine; Cisplatin; Cyclophosphamide; Dacarbazine; Humans; Infections; Met | 1980 |
Four-cycle high-dose therapy with hematopoietic support for metastatic breast cancer: no improvement in outcomes compared with single-course high-dose therapy.
Topics: Adjuvants, Pharmaceutic; Adult; Antineoplastic Combined Chemotherapy Protocols; Blood Transfusion; B | 2000 |
Long-term follow-up of autologous stem-cell transplantation for follicular and transformed follicular lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Purging; Carmustine; Cataract; Co | 2000 |
Immune reconstitution after autologous hematopoietic stem cell transplantation in relation to underlying disease, type of high-dose therapy and infectious complications.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Breast Neoplasms; Carmu | 2000 |
Feasibility and toxicity of high-dose chemotherapy supported by peripheral blood stem cell transplantation in elderly patients (>/=60 years) with non-Hodgkin's lymphoma: comparison with patients <60 years treated within the same protocol.
Topics: Adolescent; Adult; Age Factors; Aged; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols | 2000 |
Low infectious morbidity after intensive chemotherapy and autologous peripheral blood progenitor cell transplantation in the outpatient setting for women with breast cancer.
Topics: Adult; Aged; Ambulatory Care; Ambulatory Care Facilities; Anti-Infective Agents; Antibiotic Prophyla | 2001 |
High-dose therapy in patients with Hodgkin's disease: the use of selected CD34(+) cells is as safe as unmanipulated peripheral blood progenitor cells.
Topics: Adolescent; Adult; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combi | 2001 |
Repeated high-dose chemotherapy followed by purged autologous bone marrow transplantation as consolidation therapy in metastatic neuroblastoma.
Topics: Abdominal Neoplasms; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Disease | 1987 |
Intensive chemotherapy in children with acute lymphoblastic leukemia (L-2 protocol).
Topics: Administration, Oral; Adolescent; Age Factors; Antineoplastic Agents; Asparaginase; Carmustine; Chem | 1974 |